University of Texas MD Anderson Cancer Center
Houston, United States
Scott Kopetz, M.D., Ph.D., is currently Deputy Chair of the Department of Gastrointestinal Medical Oncology and Program Leader of the GI Program of the Cancer Center Support Grant at UTMDACC. Dr. Kopetz is well versed in multidisciplinary care of and translational research for GI cancer patients. His laboratory is funded by multiple NIH-funded grants. He serves as Chair of the Colon Cancer Task Force and is Vice-Chair for Colon Cancer in the NSABP/RTG/GOG (NRG) Cooperative Group. Dr. Kopetz is a leader of the GI Cancer Center Support Grant at MD Anderson and the Colorectal Cancer Moonshot, a multi-disciplinary effort to improve the survival of this disease beyond incremental advances. He has authored over 300 peer- reviewed articles in respected scientific journals. He is a senior editor for Clinical Cancer Research. Dr. Kopetz has developed a translational and clinical trial program in BRAF-mutated colorectal cancer, which has resulted in addition of combination therapy with a BRAF inhibitor to the current treatment guidelines. He also co-led the clinical trial resulting in the FDA-approval of nivolumab and ipilimumab for mismatch repair deficient tumors. He also is an innovator in the development and implementation of circulating tumor DNA into clinical management, including interrogation of mechanisms of resistance, evaluation of minimal residual disease, and integration into clinical trial designs. Further research efforts include the development of the Consensus Molecular Subtypes, an RNA- based methodology for CRC classification that is now being widely integrated in retrospective and clinical trial efforts.
Thursday, June 30, 2022
18:50 – 19:50
Saturday, July 2, 2022
12:15 – 12:35